Regeneron Pharmaceuticals, Inc. Class Action Lawsuit Overview
The Gross Law Firm is informing investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about an important class action lawsuit that has emerged recently. This notice is crucial for any shareholders who purchased shares of the company during the specified class period, encouraging them to reach out for potential participation.
Who Should Take Action?
If you are a shareholder who bought shares of REGN, it is vital to contact the Gross Law Firm to explore the possibility of being appointed as a lead plaintiff. It’s important to note that you don’t have to be appointed as a lead plaintiff to obtain compensation from this lawsuit.
Class Period Details
The class period for this lawsuit spans from November 2, 2023, to October 30, 2024. This period is critical for identifying those shareholders who may be eligible to participate in the case.
Allegations Against Regeneron Pharmaceuticals
According to the allegations, during the class period, Regeneron issued misleading statements and failed to disclose specific financial practices that could jeopardize shareholder interests. The complaint specifically mentions that the company made payments to distributors related to credit card fees while not revealing these as price concessions, misleading customers and investors alike. This practice not only impacted the selling price of Eylea, one of Regeneron's significant products, but also inflated sales figures that were reported.
The claims further state that by not accurately reporting these payment practices, Regeneron misled federal agencies and violated the False Claims Act, raising concerns over the integrity of the company's operations.
Important Deadline for Shareholders
The deadline for shareholders to register for participation in this class action is set for March 10, 2025. Those interested must act promptly to ensure their rights are protected.
Next Steps for Interested Investors
Once you’ve registered as a shareholder during the mentioned period, you will gain access to portfolio monitoring tools which will keep you informed about any updates throughout the course of the lawsuit. Remember, there is no obligation or cost attached to this participation.
Why Choose the Gross Law Firm?
The Gross Law Firm is recognized nationally for its commitment to class action cases, focusing on protecting the rights of investors facing losses due to deceit or unethical corporate practices. Their mission emphasizes the necessity for companies to adhere to responsible business methods and act in the best interest of their stakeholders. As champions for investors, they seek to recover losses incurred when misleading information artificially inflates a stock's value, ensuring all stakeholders are treated fairly.
Contact Information
For those who need to inquire further or wish to participate in the class action, here is the contact information for the Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Regeneron Pharmaceuticals lawsuit?
The class period for the lawsuit runs from November 2, 2023, to October 30, 2024.
What should shareholders do if they wish to participate in the lawsuit?
Shareholders are encouraged to contact the Gross Law Firm to express their interest and register for participation by the deadline of March 10, 2025.
What allegations are being made against Regeneron Pharmaceuticals?
The allegations include misleading statements regarding credit card payment practices that inflated reported sales figures for Eylea.
Is there any cost to participate in the class action?
No, there is no cost or obligation to join the class action lawsuit.
How can I contact the Gross Law Firm?
You can contact the Gross Law Firm via phone at (646) 453-8903 for any inquiries related to the lawsuit.
